clinical trial · NCT04678479
Ganaxolone Expanded Access Program Compassionate Use
CDKL5 DisorderGanaxolone
brief summary
The primary objective is to provide GNX to patients ≥ 2 years with CDD-related seizures who are refractory to, or intolerant of, standard therapy.
started
—
primary completion
—
completion
—
last updated
Jan 22, 2024
detailed description
This is a multi-center, long-term, open-label, expanded access protocol of adjunctive GNX treatment in children, adolescents, and adults with CDD. Patients with inadequate seizure control on their current anti seizure medications at therapeutic doses will be eligible for enrollment.
official title
Expanded Access With Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin Dependent Kinase-like 5 Deficiency Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol